Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.18 | 0.02 | -0.18 |
| FCF Yield | -11.63% | -5.96% | -28.01% | -22.88% |
| EV / EBITDA | -10.34 | 112.68 | -1.87 | -3.91 |
| Quality | ||||
| ROIC | -37.02% | -39.44% | -133.17% | -103.05% |
| Gross Margin | 68.95% | 58.82% | 59.34% | 70.51% |
| Cash Conversion Ratio | 0.81 | 0.81 | 0.18 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.48% | -0.16% | 1.31% | -1.14% |
| Free Cash Flow Growth | -387.02% | 40.10% | 63.67% | 26.28% |
| Safety | ||||
| Net Debt / EBITDA | 1.26 | 7.99 | -0.76 | -0.63 |
| Interest Coverage | -1.83 | -2.02 | -3.38 | -1.54 |
| Efficiency | ||||
| Inventory Turnover | 2.96 | 3.08 | 3.35 | 3.71 |
| Cash Conversion Cycle | -40.09 | 23.33 | -42.43 | -17.10 |